AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 161 min read$MPLT

Kroeger Christopher A. sold $595K of MPLT

Kroeger Christopher A. (Chief Executive Officer) sold 73,691 shares of MapLight Therapeutics, Inc. (MPLT) at $8.08 ($0.60M total) on 2026-10-15.

Original reporting
SEC EDGAR · Kroeger Christopher A.
Published Oct 16, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MPLT
Neutral
medium confidence
Mentioned
$MPLT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MPLTNeutralLow
01

Why it matters

The transaction provides fresh data on insider holdings, useful for short‑term sentiment but unlikely to drive major price moves.

02

Market read

A modest insider sell by the CEO of a micro‑cap biotech; limited trading relevance.

03

What to watch

The CEO retains a large stake (over 1.1M shares) and may still be bullish on the company.

Relevance 5/10Novelty 4/10Timing: after-hours filing today

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$MPLTNeutralMedium confidence
Context

CEO Christopher Kroeger sold 73,691 shares for $595K, reducing his stake to 1,195,909 shares.

Expected impact

likely slight downward pressure as the market prices in the sell-off

Evidence & confidence

A $595K sale by the CEO is material for a micro‑cap biotech, but the amount is modest relative to total shares outstanding.

Market effects

Sector

Minimal impact on the broader biotech sector; similar insider sales are common.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine liquidity move and not indicative of any negative outlook.

Key entities

  • Company
    MapLight Therapeutics, Inc.

    Biotech firm developing therapeutic candidates.

  • Person
    Christopher A. Kroeger

    Chief Executive Officer of MapLight Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MPLT insider trading history →

Related articles

AUG 13
$MPLTMed

MapLight Therapeutics, Inc. (MPLT): Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3…

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and

SEC EDGAR 8-K6 min